Blinding in clinical trials: A practical approach

Heejung Bang, Jongbae J. Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Blinding is important in the conduct of clinical trials, yet it generally receives less attention and effort than other trial components (e.g., randomization, compliance) that are rigorously treated in the design and/or analysis stages. Furthermore, although the word "blind" commonly appears in the titles of publications, its use is not always well justified. We are human beings, and our behavior or decisions can change depending on whether our eyes are open or closed. That is why virtually everyone in the clinical trial community, including subjects, investigators, treating practitioners, and outcome assessors, would agree that some form of blinding is needed to reach a fair and objective conclusion uninfluenced by knowledge of intervention assignment. Despite our best efforts, however, blinding may not always be successful. There is a considerable body of literature about blinding and the need to assess whether it has been properly implemented and maintained. By discussing how the trialist and the team may handle blinding-related issues in different stages of a clinical trial, this brief article intends to offer reasonable suggestions that could improve current practice, helping researchers deal confidently with blinding-related issues and research in a manner that meets rigorous standards, but is practical and flexible.

Original languageEnglish (US)
Pages (from-to)367-369
Number of pages3
JournalJournal of Alternative and Complementary Medicine
Volume19
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Pragmatic Clinical Trials
Clinical Trials
Research Personnel
Random Allocation
Compliance
Publications
Research

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Blinding in clinical trials : A practical approach. / Bang, Heejung; Park, Jongbae J.

In: Journal of Alternative and Complementary Medicine, Vol. 19, No. 4, 01.04.2013, p. 367-369.

Research output: Contribution to journalArticle

@article{26a3d774e4044f16a1c2c8b16949ead1,
title = "Blinding in clinical trials: A practical approach",
abstract = "Blinding is important in the conduct of clinical trials, yet it generally receives less attention and effort than other trial components (e.g., randomization, compliance) that are rigorously treated in the design and/or analysis stages. Furthermore, although the word {"}blind{"} commonly appears in the titles of publications, its use is not always well justified. We are human beings, and our behavior or decisions can change depending on whether our eyes are open or closed. That is why virtually everyone in the clinical trial community, including subjects, investigators, treating practitioners, and outcome assessors, would agree that some form of blinding is needed to reach a fair and objective conclusion uninfluenced by knowledge of intervention assignment. Despite our best efforts, however, blinding may not always be successful. There is a considerable body of literature about blinding and the need to assess whether it has been properly implemented and maintained. By discussing how the trialist and the team may handle blinding-related issues in different stages of a clinical trial, this brief article intends to offer reasonable suggestions that could improve current practice, helping researchers deal confidently with blinding-related issues and research in a manner that meets rigorous standards, but is practical and flexible.",
author = "Heejung Bang and Park, {Jongbae J.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1089/acm.2012.0210",
language = "English (US)",
volume = "19",
pages = "367--369",
journal = "Journal of Alternative and Complementary Medicine",
issn = "1075-5535",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Blinding in clinical trials

T2 - A practical approach

AU - Bang, Heejung

AU - Park, Jongbae J.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Blinding is important in the conduct of clinical trials, yet it generally receives less attention and effort than other trial components (e.g., randomization, compliance) that are rigorously treated in the design and/or analysis stages. Furthermore, although the word "blind" commonly appears in the titles of publications, its use is not always well justified. We are human beings, and our behavior or decisions can change depending on whether our eyes are open or closed. That is why virtually everyone in the clinical trial community, including subjects, investigators, treating practitioners, and outcome assessors, would agree that some form of blinding is needed to reach a fair and objective conclusion uninfluenced by knowledge of intervention assignment. Despite our best efforts, however, blinding may not always be successful. There is a considerable body of literature about blinding and the need to assess whether it has been properly implemented and maintained. By discussing how the trialist and the team may handle blinding-related issues in different stages of a clinical trial, this brief article intends to offer reasonable suggestions that could improve current practice, helping researchers deal confidently with blinding-related issues and research in a manner that meets rigorous standards, but is practical and flexible.

AB - Blinding is important in the conduct of clinical trials, yet it generally receives less attention and effort than other trial components (e.g., randomization, compliance) that are rigorously treated in the design and/or analysis stages. Furthermore, although the word "blind" commonly appears in the titles of publications, its use is not always well justified. We are human beings, and our behavior or decisions can change depending on whether our eyes are open or closed. That is why virtually everyone in the clinical trial community, including subjects, investigators, treating practitioners, and outcome assessors, would agree that some form of blinding is needed to reach a fair and objective conclusion uninfluenced by knowledge of intervention assignment. Despite our best efforts, however, blinding may not always be successful. There is a considerable body of literature about blinding and the need to assess whether it has been properly implemented and maintained. By discussing how the trialist and the team may handle blinding-related issues in different stages of a clinical trial, this brief article intends to offer reasonable suggestions that could improve current practice, helping researchers deal confidently with blinding-related issues and research in a manner that meets rigorous standards, but is practical and flexible.

UR - http://www.scopus.com/inward/record.url?scp=84876367617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876367617&partnerID=8YFLogxK

U2 - 10.1089/acm.2012.0210

DO - 10.1089/acm.2012.0210

M3 - Article

C2 - 23140113

AN - SCOPUS:84876367617

VL - 19

SP - 367

EP - 369

JO - Journal of Alternative and Complementary Medicine

JF - Journal of Alternative and Complementary Medicine

SN - 1075-5535

IS - 4

ER -